Saturday 17 October 2026
Export MDGL’s income statement to Excel — free account
Madrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.
449.74
10.07
−2.19%
Follow MDGL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.19 | 13.42 | 13.63 | 13.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
670.81 | (90.77) | (97.89) | 129.14 | |
P/B ratio |
29.88 | 27.96 | 21.68 | 16.48 | |
Price to Tangible BV |
30.30 | 28.34 | 21.95 | 16.68 | |
EV/Sales |
11.80 | 13.00 | 12.95 | 12.88 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(76.63) | (54.90) | (65.50) | (59.39) | |
EV/FCF |
(72.40) | (53.41) | (64.00) | (57.61) | |
Quick Ratio |
2.76 | 2.97 | 3.62 | 3.14 | |
Current Ratio |
3.20 | 3.50 | 4.01 | 3.44 | |
Net Debt/EBITDA |
9.09 | 5.22 | 11.34 | 6.94 | |
Debt/Assets |
27.38% | 27.73% | 26.98% | 24.94% | |
Debt/Equity |
0.65 | 0.63 | 0.56 | 0.54 | |
Asset Turnover |
1.14 | 1.02 | 0.83 | 0.61 | |
Operating CF/Net income |
(0.40) | 1.77 | 2.28 | (0.70) | |
Capex/Depreciation |
(2.85) | (3.10) | 0.16 | (1.72) | |
Interest Coverage |
(7.09) | (11.86) | (7.18) | (15.30) | |
Research and Development Expense of Revenue |
25.03% | 34.91% | 36.21% | 60.57% | |
Selling, General and Administrative Expense of Revenue |
79.44% | 86.25% | 74.74% | 72.80% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
9.71% | 10.93% | 8.03% | 9.14% | |
Graham Net Nets |
0.03 | 0.03 | 0.05 | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.40%) | (2.37%) | (2.02%) | (2.59%) | |
Free Cash Flow Yield |
(1.34%) | (1.81%) | (1.48%) | (1.61%) | |
Revenue per Share |
12.50 | 10.72 | 14.31 | 12.78 | |
Operating CF per Share |
0.80 | (5.77) | (5.95) | 3.55 | |
Capex per Share |
(0.15) | (0.13) | 0.02 | (0.17) | |
Free Cash Flow per Share |
0.65 | (5.90) | (5.93) | 3.38 | |
Cash per Share |
28.78 | 28.17 | 44.07 | 49.58 | |
Shareholders Equity per Share |
17.97 | 18.72 | 26.87 | 27.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.97 | 18.72 | 26.87 | 27.83 | |
Free Cash Flow |
19.08 | (171.28) | (133.07) | 75.99 | |
Working Capital |
824.98 | 844.05 | 935.48 | 955.27 | |
Capital Expenditures |
(4.25) | (3.85) | 0.39 | (3.86) | |
Net Current Asset Value |
478.26 | 498.43 | 588.87 | 609.96 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
135.77 | 124.39 | 94.15 | 71.87 | |
Average Payables |
36.24 | 51.43 | 46.24 | 45.45 | |
Average Inventory |
81.44 | 83.66 | 54.45 | 39.02 | |
Average Assets |
1,130.01 | 1,111.98 | 1,150.92 | 1,217.86 | |
Average Common Equity |
609.85 | 627.05 | 678.54 | 701.44 |
Columns are period end dates